Jeff Pavell
About Jeff Pavell
Dr. Jeff Pavell (age 58 as of the 2025 record date) has served as an independent director of Silo Pharma since September 2022. He is a board-certified physiatrist, Chief of Rehabilitation Medicine at Englewood Health since January 2017, and holds a D.O. (New York College of Osteopathic Medicine) and a B.A. from Johns Hopkins University; he is certified in pain medicine and focuses on non-operative spine, sports and interventional pain treatments . He was re-elected to the SILO board at the October 24, 2025 annual meeting, indicating continued shareholder support .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Englewood Health | Chief of Rehabilitation Medicine | Since Jan 2017–present | Leads rehabilitation medicine function |
| NewYork-Presbyterian Columbia University Irving Medical Center | Teaching Staff | Since Nov 2005–present | Academic teaching responsibilities |
| Hackensack Meridian School of Medicine at Seton Hall | Teaching Staff | Since Dec 2020–present | Academic teaching responsibilities |
| Patient Care Associates (outpatient surgical center) | Partner | Since 2010–present | Clinical operations partner |
| The Physical Medicine and Rehabilitation Center (private practice) | Partner | Since 2002–present | Practice focused on spine, sports, occupational injuries |
External Roles
| Organization | Ticker | Role | Tenure | Notes |
|---|---|---|---|---|
| Hoth Therapeutics, Inc. | HOTH | Director | Since Dec 2022–present | Public company directorship |
Interlock note: Another SILO director, Wayne D. Linsley, is also a director at Hoth Therapeutics (since April 2020), creating a shared external board connection among SILO directors .
Board Governance
- Independence: The Board determined Dr. Pavell is independent under Nasdaq rules; he serves on all three standing committees (Audit; Compensation; Nominating & Corporate Governance). He is not designated the audit committee financial expert (the Board identified Wayne D. Linsley as the financial expert) .
- Committee assignments and chair roles:
- Audit Committee: Member (Chair: Wayne D. Linsley). All members meet Rule 10A-3 independence; all meet Nasdaq financial literacy .
- Compensation Committee: Member (Chair: Wayne D. Linsley). Independent under Nasdaq rules .
- Nominating & Corporate Governance Committee: Member (Chair: Wayne D. Linsley). Independent under Nasdaq rules .
- Attendance and engagement: Proxy states all audit/comp/nom-gov committee members attended all meetings during FY2024; none of the directors attended fewer than 75% of total Board and committee meetings in 2024 .
- Board structure: CEO Eric Weisblum is also Chairman; the Board has no lead independent director and believes a lead role is not necessary at this time given size/structure .
- Years of service on SILO board: Director since September 2022 .
- Shareholder support: Re-elected on Oct 24, 2025 with 1,763,884 votes “For,” 108,115 “Withhold” (broker non-votes 3,280,416) .
Fixed Compensation
| Component | Amount | Period/Notes |
|---|---|---|
| Cash retainer (fees earned/paid in cash) | $25,000 | Reported for non-employee director compensation; no additional stock/option awards shown for Dr. Pavell in the reported period |
| Equity (stock awards) | $0 | No director stock awards disclosed for the period |
| Equity (option awards) | $0 | No director option awards disclosed for the period |
| Meeting/committee fees | Not separately disclosed | Program comprises cash and equity; only cash fees shown for Dr. Pavell in 2024 |
Performance Compensation
- No performance-based director awards or metrics disclosed for Dr. Pavell in the reported period. The proxy notes that, other than amounts in the director compensation table, the Company did not pay any other compensation, make equity awards or non‑equity awards to non‑employee directors in 2024 .
Other Directorships & Interlocks
| Company | Role | Committee Roles (if disclosed) | Overlap/Interlock |
|---|---|---|---|
| Hoth Therapeutics, Inc. (NASDAQ: HOTH) | Director | Not disclosed | Shared board overlap with SILO director Wayne D. Linsley (also a HOTH director) |
- Compensation Committee Interlocks: None. The proxy states no executive officer served on another entity’s board/comp committee that had an executive officer on SILO’s board/comp committee; and no comp committee member has ever been a SILO officer or employee .
Expertise & Qualifications
- Clinical expertise in physical medicine and rehabilitation; certified in pain medicine with advanced non-operative spine and interventional pain focus .
- Senior clinical leadership (Chief of Rehabilitation Medicine, Englewood Health) and long-standing academic appointments (NYP/Columbia; Hackensack Meridian School of Medicine) .
- Not designated as the audit committee financial expert (that designation is held by Wayne D. Linsley) .
Equity Ownership
| Category | Detail |
|---|---|
| Beneficial ownership (common shares) | 0 shares beneficially owned as of the record date (9,461,128 shares outstanding) |
| Ownership % | 0.00% (below 1% threshold reported in proxy table) |
| Options/RSUs reported | None reported for Dr. Pavell in beneficial ownership table; options disclosed for another director (Linsley) but not for Dr. Pavell |
| Pledging/Hedging | Insider Trading Policy prohibits short sales, hedging/monetization, and derivative transactions; pledging requires preclearance. As of Dec 31, 2024, none of the directors or executive officers had pledged any shares |
Governance Assessment
- Strengths
- Independent director serving on all three standing committees; reported perfect committee meeting attendance and overall compliance with meeting attendance thresholds, signaling engagement .
- Shareholder support: re-elected with 1,763,884 votes “For” vs. 108,115 “Withhold,” indicating strong support among votes cast (excluding broker non‑votes) .
- No related-party transactions above disclosure thresholds; no family relationships; no delinquent Section 16 filings reported for 2024 .
- Anti-hedging/pledging policy in place, with no pledges outstanding as of year-end 2024 .
- Watch items / potential red flags
- Ownership alignment: 0 shares beneficially owned; no director equity awards reported for 2024. Low personal ownership can weaken alignment with shareholders for a micro-cap clinical-stage company .
- Board leadership structure: CEO also serves as Chairman; no lead independent director, which can concentrate power, although the Board defends the structure due to company size .
- Equity plan expansion and evergreen: In 2025, the Board sought and received approval to expand the Amended and Restated 2020 Plan to 1,400,000 shares plus an evergreen up to 5% annually—introducing ongoing dilution risk if heavily utilized .
- Listing risk backdrop: Reverse stock split authorization to address Nasdaq $1.00 bid deficiency—an operating environment signal rather than a director-specific issue, but relevant to investor confidence .
Shareholder Vote Support (2025 Annual Meeting)
| Nominee | For | Withhold | Broker Non-Votes |
|---|---|---|---|
| Dr. Jeff Pavell | 1,763,884 | 108,115 | 3,280,416 |
Related-Party & Conflicts Check
- Related-party transactions: None during FY2024–FY2025 above the lesser of $120,000 or 1% of average total assets; no current related-party transactions proposed .
- Family relationships: None among directors/executive officers .
- Legal/Regulatory: No material proceedings or disqualifying legal events disclosed for directors .
Director Compensation Program Context
- Program uses cash and equity elements; however, during 2024, non-employee directors received cash retainers and no equity was awarded to Dr. Pavell per the disclosed table .
- No equity grant timing concerns disclosed; Company states it has not intentionally timed grants around material nonpublic information .
Committee Workload and Meeting Attendance (Context)
- Audit: Committee independence affirmed; all members financially literate; report included with 2024 10-K recommendation .
- Across Board/Committees: Disclosure states no director attended fewer than 75% of Board and committee meetings in 2024; all members of the committees attended all committee meetings .
Overall implication: Dr. Pavell is an engaged, independent director with deep clinical governance expertise and strong 2025 re‑election support. The principal governance alignment gap is zero share ownership and the absence of director equity awards in 2024, while the broader board structure (combined CEO/Chair, no lead independent) and equity plan evergreen may be viewed skeptically by some investors focused on dilution and independent oversight .